Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This will be a double-blind, randomized, placebo-controlled, parallel group study. The
purpose of this study is to investigate the efficacy and safety of Cavosonstat (N91115) in
adult patients with CF who are homozygous for the F508del-CFTR mutation and being treated
with lumacaftor/ivacaftor (Orkambi™).